@article{yih_intussusception_2014,
	title = {Intussusception {Risk} after {Rotavirus} {Vaccination} in {U}.{S}. {Infants}},
	volume = {370},
	issn = {0028-4793},
	url = {http://www.nejm.org/doi/full/10.1056/NEJMoa1303164},
	doi = {10.1056/NEJMoa1303164},
	abstract = {In 1999, a tetravalent rhesus–human reassortant rotavirus vaccine (RotaShield, Wyeth Lederle) was voluntarily withdrawn from the U.S. market within a year after licensure owing to an association with intussusception. The excess risk of intussusception was estimated at approximately 1 to 2 cases per 10,000 recipients of the vaccine.1 In 2006 and 2008, respectively, a pentavalent bovine–human reassortant rotavirus vaccine (RV5; RotaTeq, Merck) and a monovalent human rotavirus vaccine (RV1; Rotarix, GlaxoSmithKline) were licensed after evaluation in clinical trials involving more than 60,000 infants, which provided enough statistical power to allow detection of an intussusception risk of a magnitude similar to . . .},
	number = {6},
	urldate = {2014-07-29},
	journal = {New England Journal of Medicine},
	author = {Yih, W. Katherine and Lieu, Tracy A. and Kulldorff, Martin and Martin, David and McMahill-Walraven, Cheryl N. and Platt, Richard and Selvam, Nandini and Selvan, Mano and Lee, Grace M. and Nguyen, Michael},
	year = {2014},
	pmid = {24422676},
	keywords = {\#duplicates, Cohort Studies, Humans, Immunization, Secondary, Infant, Intussusception/epidemiology/*etiology, Rotavirus Vaccines/administration \& dosage/*adverse effects, United States/epidemiology, Vaccines, Attenuated/administration \& dosage/adverse effects, risk},
	pages = {503--512},
}

{"_id":"JoMAvNbRR5ALuuQFb","bibbaseid":"yih-lieu-kulldorff-martin-mcmahillwalraven-platt-selvam-selvan-etal-intussusceptionriskafterrotavirusvaccinationinusinfants-2014","author_short":["Yih, W. K.","Lieu, T. A.","Kulldorff, M.","Martin, D.","McMahill-Walraven, C. N.","Platt, R.","Selvam, N.","Selvan, M.","Lee, G. M.","Nguyen, M."],"bibdata":{"bibtype":"article","type":"article","title":"Intussusception Risk after Rotavirus Vaccination in U.S. Infants","volume":"370","issn":"0028-4793","url":"http://www.nejm.org/doi/full/10.1056/NEJMoa1303164","doi":"10.1056/NEJMoa1303164","abstract":"In 1999, a tetravalent rhesus–human reassortant rotavirus vaccine (RotaShield, Wyeth Lederle) was voluntarily withdrawn from the U.S. market within a year after licensure owing to an association with intussusception. The excess risk of intussusception was estimated at approximately 1 to 2 cases per 10,000 recipients of the vaccine.1 In 2006 and 2008, respectively, a pentavalent bovine–human reassortant rotavirus vaccine (RV5; RotaTeq, Merck) and a monovalent human rotavirus vaccine (RV1; Rotarix, GlaxoSmithKline) were licensed after evaluation in clinical trials involving more than 60,000 infants, which provided enough statistical power to allow detection of an intussusception risk of a magnitude similar to . . .","number":"6","urldate":"2014-07-29","journal":"New England Journal of Medicine","author":[{"propositions":[],"lastnames":["Yih"],"firstnames":["W.","Katherine"],"suffixes":[]},{"propositions":[],"lastnames":["Lieu"],"firstnames":["Tracy","A."],"suffixes":[]},{"propositions":[],"lastnames":["Kulldorff"],"firstnames":["Martin"],"suffixes":[]},{"propositions":[],"lastnames":["Martin"],"firstnames":["David"],"suffixes":[]},{"propositions":[],"lastnames":["McMahill-Walraven"],"firstnames":["Cheryl","N."],"suffixes":[]},{"propositions":[],"lastnames":["Platt"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Selvam"],"firstnames":["Nandini"],"suffixes":[]},{"propositions":[],"lastnames":["Selvan"],"firstnames":["Mano"],"suffixes":[]},{"propositions":[],"lastnames":["Lee"],"firstnames":["Grace","M."],"suffixes":[]},{"propositions":[],"lastnames":["Nguyen"],"firstnames":["Michael"],"suffixes":[]}],"year":"2014","pmid":"24422676","keywords":"#duplicates, Cohort Studies, Humans, Immunization, Secondary, Infant, Intussusception/epidemiology/*etiology, Rotavirus Vaccines/administration & dosage/*adverse effects, United States/epidemiology, Vaccines, Attenuated/administration & dosage/adverse effects, risk","pages":"503–512","bibtex":"@article{yih_intussusception_2014,\n\ttitle = {Intussusception {Risk} after {Rotavirus} {Vaccination} in {U}.{S}. {Infants}},\n\tvolume = {370},\n\tissn = {0028-4793},\n\turl = {http://www.nejm.org/doi/full/10.1056/NEJMoa1303164},\n\tdoi = {10.1056/NEJMoa1303164},\n\tabstract = {In 1999, a tetravalent rhesus–human reassortant rotavirus vaccine (RotaShield, Wyeth Lederle) was voluntarily withdrawn from the U.S. market within a year after licensure owing to an association with intussusception. The excess risk of intussusception was estimated at approximately 1 to 2 cases per 10,000 recipients of the vaccine.1 In 2006 and 2008, respectively, a pentavalent bovine–human reassortant rotavirus vaccine (RV5; RotaTeq, Merck) and a monovalent human rotavirus vaccine (RV1; Rotarix, GlaxoSmithKline) were licensed after evaluation in clinical trials involving more than 60,000 infants, which provided enough statistical power to allow detection of an intussusception risk of a magnitude similar to . . .},\n\tnumber = {6},\n\turldate = {2014-07-29},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Yih, W. Katherine and Lieu, Tracy A. and Kulldorff, Martin and Martin, David and McMahill-Walraven, Cheryl N. and Platt, Richard and Selvam, Nandini and Selvan, Mano and Lee, Grace M. and Nguyen, Michael},\n\tyear = {2014},\n\tpmid = {24422676},\n\tkeywords = {\\#duplicates, Cohort Studies, Humans, Immunization, Secondary, Infant, Intussusception/epidemiology/*etiology, Rotavirus Vaccines/administration \\& dosage/*adverse effects, United States/epidemiology, Vaccines, Attenuated/administration \\& dosage/adverse effects, risk},\n\tpages = {503--512},\n}\n\n","author_short":["Yih, W. K.","Lieu, T. A.","Kulldorff, M.","Martin, D.","McMahill-Walraven, C. N.","Platt, R.","Selvam, N.","Selvan, M.","Lee, G. M.","Nguyen, M."],"key":"yih_intussusception_2014","id":"yih_intussusception_2014","bibbaseid":"yih-lieu-kulldorff-martin-mcmahillwalraven-platt-selvam-selvan-etal-intussusceptionriskafterrotavirusvaccinationinusinfants-2014","role":"author","urls":{"Paper":"http://www.nejm.org/doi/full/10.1056/NEJMoa1303164"},"keyword":["#duplicates","Cohort Studies","Humans","Immunization","Secondary","Infant","Intussusception/epidemiology/*etiology","Rotavirus Vaccines/administration & dosage/*adverse effects","United States/epidemiology","Vaccines","Attenuated/administration & dosage/adverse effects","risk"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":["#duplicates","cohort studies","humans","immunization","secondary","infant","intussusception/epidemiology/*etiology","rotavirus vaccines/administration & dosage/*adverse effects","united states/epidemiology","vaccines","attenuated/administration & dosage/adverse effects","risk"],"search_terms":["intussusception","risk","rotavirus","vaccination","infants","yih","lieu","kulldorff","martin","mcmahill-walraven","platt","selvam","selvan","lee","nguyen"],"title":"Intussusception Risk after Rotavirus Vaccination in U.S. Infants","year":2014}